An observational study in Stroke, sponsored by Wuhan General Hospital of Guangzhou Military Command. Status unknown. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-10.
Sponsored by Wuhan General Hospital of Guangzhou Military Command · Observational
The time window for intravenous recombinant tissue plasminogen activator treatment in ischemic stroke patients has been extended to 4.5h. Little is known about intravenous recombinant tissue plasminogen activator use in the 3-4.5 hour time window among Chinese stroke patients. This exploratory study was to describe the feasibility and outcome of treatment with intravenous recombinant tissue plasminogen activator in the expanded time window, and to offer suggestions for future clinical work in China.
Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was assessed by absolute changes in the National Institute of Health Stroke Scale score at 24 hours and by the improvement of modified Rankin Scale score at discharge or 6-month follow-up. The safety of intravenous recombinant tissue plasminogen activator was assessed by the rate of mortality, intracerebral hemorrhage and other common complications. Multivariate logistic regression models were used to evaluate factors associated with favorable clinical outcome.
7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.
This study's planned enrollment of 200 is above the median of 160 across 1,729 observational studies indexed under Stroke.
Browse Stroke studies →Wuhan General Hospital of Guangzhou Military Command is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
stroke patients in the 3-4.5 hour time window
Inclusion Criteria:stroke patients in the 3-4.5 hour time window -
Exclusion Criteria:stroke patients in more than 4.5 hour time window
-
Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
Drug: IV rt-PA
One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
Drug: IV rt-PA
IV rt-PA treatment
Also known as: rt-PA
National Institute of Health Stroke Scale score and modified Rankin Scale
Favorable clinical outcome of intravenous recombinant tissue plasminogen activator was assessed by absolute changes in the National Institute of Health Stroke Scale score at 24 hours and by the improvement of modified Rankin Scale score at discharge or 6-month follow-up
Time frame: Outcome measure will be assessed at 24 weeks
No study locations are listed for this record.
The record gives a start of Jan 2008, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wuhan General Hospital of Guangzhou Military Command